Elevated glutamine but not glutamate is associated with clozapine eligibility in an early psychosis sample
Datos Bibliográficos
| ID | 15519679 |
|---|---|
| Autores | Maxwell Seward (Dalhousie University, autor de correspondencia), Esther Puiras (Nova Scotia Health Authority), Temi Toba-Oluboka (0000-0001-6047-0766, Nova Scotia Health Authority), Candice E Crocker (0000-0001-8102-1716, Dalhousie University), Philip G Tibbo (0000-0002-2070-6495, Dalhousie University), Kara Dempster (0000-0002-5903-5051, Dalhousie University) |
| Año | 2026 |
| Volumen | 17 |
| Páginas | 1762696-1762696 |
| Fecha de publicación | 2026-02-24 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Frontiers in Psychiatry (JOURNAL) |
| Identificadores de la revista | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Editorial | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2026.1762696 |
| PMID | 41816535 |
| OpenAlex | W7131313260 |
| Idioma | EN |
| Referencias citadas | 66 |
While elevated ACC glutamate has been associated with poor response to antipsychotic medications in early psychosis samples, this is the first study to explore the association with clozapine eligibility. Contrary to our hypothesis, ACC glutamate was not higher in the CE group. However, glutamine, a precursor to glutamate, was higher in the CE group, in line with previous studies that have found elevated glutamatergic metabolites to be associated with poor treatment response to antipsychotic medication. Our results support future studies to further characterize the neurobiology of clozapine eligibility in early-phase psychosis to assist in the timely initiation of clozapine to maximize outcomes
Antipsychotic · Clozapine · Early psychosis · Glutamate receptor · Glutamine · Psychosis · Schizophrenia (object-oriented programming · Functional Brain Connectivity Studies · Schizophrenia research and treatment · Treatment of Major Depression
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |